Diligence memo · auto-generated · as of July 3, 2026

Paragon Bioservices, Inc.

Paragon Bioservices, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Paragon Bioservices, Inc. operates in Biotechnology, based in BALTIMORE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Paragon Bioservices, Inc. has raised $23M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $14M on 2014-10-22.

Most recent recorded round closed around 2018-08-03.

Valuation (modeled)modeled

Provath models Paragon Bioservices, Inc. at approximately $181M (range $5.5M–$983M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.86× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 15 months.

Last raise 7.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 2.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 70% of Biotechnology peers (4293 compared).

Modeled value ranks above 71% of those peers.

Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.